SCHEMBL4683689

SCHEMBL4683689

O=c1c(-c2ccc(F)cc2)coc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 1.00
ALDH1A1 P00352 6/20 1.00
HSD17B10 Q99714 6/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
NPC1 O15118 5/20 1.00
RAB9A P51151 5/20 1.00
HPGD P15428 5/20 1.00
PPARG P37231 4/20 1.00
PPARD Q03181 4/20 1.00
PPARA Q07869 4/20 1.00
GAA P10253 1/20 1.00
MAOA P21397 5/20 0.83
MAOB P27338 5/20 0.83
ALDH2 P05091 5/20 0.83
MAPT P10636 4/20 0.83
TP53 P04637 3/20 0.83
CYP3A4 P08684 3/20 0.83
CYP2D6 P10635 2/20 0.83
CYP2C9 P11712 2/20 0.83
CYP2C19 P33261 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Daidzein SCHEMBL29374778 0.91 KDM4E (1.00) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
Daidzein SCHEMBL21114371 0.91 KDM4E (1.00) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
Daidzein SCHEMBL19814 0.91 KDM4E (1.00) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL5383815 0.88 KDM4E (0.78) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
Daidzein SCHEMBL19410270 0.87 KDM4E (0.86) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL30432969 0.85 KDM4E (0.83) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL2349506 0.85 KDM4E (0.83) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL2549643 0.85 KDM4E (0.83) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL12289059 0.85 KDM4E (0.83) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL4684766 0.85 KDM4E (0.83) KDM4EALDH1A1HSD17B10SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009026658-A1 PPAR AGONISTS THE UNIVERSITY OF SYDNEY (AU) 2009-03-05 WO disclosed
WO-2009026657-A1 FLAVONOID PPAR AGONISTS THE UNIVERSITY OF SYDNEY (AU) 2009-03-05 WO disclosed
EP-1542675-A4 COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH ENDOWMENT FOR RES IN HUMAN BIO (US) 2008-11-19 EP disclosed
US-7368434-B2 Compounds useful for the inhibition of ALDH THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 2008-05-06 US disclosed
EP-1542675-A1 COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH The Endowment For Research In Human Biology, Inc. (US) 2005-06-22 EP disclosed
US-20040068003-A1 Compounds useful for the inhibition of ALDH THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC, 2004-04-08 US disclosed
WO-2004002470-A1 COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068003-A1 Compounds useful for the inhibition of ALDH ALDH2, ALDH1A1, ALDH3A1 KDM4E 1630/4885ALDH1A1 2/4885HSD17B10 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.